Compare Quest Diagnostics Inc (DGX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Materials Select Sector SPDR Fund — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Materials Select Sector SPDR Fund trades at $49.42 (market cap $7.73B). The key difference: Quest Diagnostics Inc is far larger — about 3.3× Materials Select Sector SPDR Fund's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| DGX | XLB | |
|---|---|---|
Market Cap | $25.48B | $7.73B |
Volume | 941,866 | 13,681,146 |
Sector | Health | — |
52-Week High | $247.45 | $53.67 |
52-Week Low | $173.49 | $42.23 |
Typical Hold Time | 56 Days | 70 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
XLB, the Materials Select Sector SPDR ETF, trades at $49.55, up 1.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The fund is heavily concentrated in chemicals (49% of assets) and faces cyclical pressures, with recent news highlighting sector volatility amid AI-driven infrastructure demand. Key support sits at $48, while resistance is at $50.
The outlook for XLB is cautious due to sector overvaluation concerns and bearish technicals. Opportunities lie in long-term infrastructure trends, but risks include economic sensitivity and high concentration. Investors should weigh cyclical exposure against potential growth from manufacturing and AI-related material demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
